Spyre Therapeutics (SYRE) Shares Outstanding (2015 - 2026)

Spyre Therapeutics' Shares Outstanding (Entity) history runs 11 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 35.87% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (up 35.87% YoY) and the FY2025 annual result came in at $2.6 million, up 4.02% from the prior year.
• Shares Outstanding (Entity) was $2.6 million for Q1 2026 at Spyre Therapeutics, down from $2.6 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $6.9 million in Q4 2023 and bottomed at $213900.0 in Q3 2025.
• A 5-year average of $2.9 million and a median of $2.9 million in 2022 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) surged 104.59% — and 2024, when it plunged 63.44%.
• Spyre Therapeutics' Shares Outstanding (Entity) stood at $3.4 million in 2022, then jumped by 104.59% to $6.9 million in 2023, then plunged by 63.44% to $2.5 million in 2024, then increased by 4.02% to $2.6 million in 2025, then fell by 1.7% to $2.6 million in 2026.
• Business Quant data shows SYRE's Shares Outstanding (Entity) at $2.6 million in Q1 2026, $2.6 million in Q4 2025, and $213900.0 in Q3 2025.